Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-02-08
2010-06-08
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S133100, C424S141100, C424S154100, C424S156100, C435S069100, C435S069600, C435S326000, C435S328000, C530S387100, C530S388100, C530S388750, C530S388850
Reexamination Certificate
active
07732578
ABSTRACT:
Disclosed herein are methods for humanizing antibodies based on selecting variable region framework sequences from human antibody genes by comparing canonical CDR structure types for CDR sequences of the variable region of a non-human antibody to canonical CDR structure types for corresponding CDRs from a library of human antibody sequences, preferably germline antibody gene segments. Human antibody variable regions having similar canonical CDR structure types to the non-human CDRs form a subset of member human antibody sequences from which to select human framework sequences. The subset members may be further ranked by amino acid similarity between the human and the non-human CDR sequences. Top ranking human sequences are selected to provide the framework sequences for constructing a chimeric antibody that functionally replaces human CDR sequences with the non-human CDR counterparts using the selected subset member human frameworks, thereby providing a humanized antibody of high affinity and low immunogenicity without need for comparing framework sequences between the non-human and human antibodies. Chimeric antibodies made according to the method are also disclosed.
REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5530101 (1996-06-01), Queen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5821337 (1998-10-01), Carter et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 5869619 (1999-02-01), Studnicka
patent: 6479284 (2002-11-01), Marasco et al.
patent: 2724393 (1996-03-01), None
Fundamental Immunology, William E. Paul, ed., 3rd Ed., pp. 292-295, 1993.
Rudikoff et al. Proc. Natl. Acad. Sci. USA, 79:1979-1983, Mar. 1982.
Colman P. M. Research in Immunology, 145:33-36, 1994.
Bendig M. M. Methods: A Companion to Methods in Enzymology, 8:83-93, 1995.
MacCallum et al. J. Mol. Biol., 262, 732-745, 1996.
Casset et al. Biochemical and Biophysical Research Communications, 307:198-205, 2003.
Holmes et al. The Journal of Immunology, 158:2192-2201, 1997.
Hwang et al. Methods, 36:35-42, 2005.
Takemura et al. FEBS Letters, 476(3):266-271, Jul. 7, 2000.
Routledge et al (1993) (Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man (Clark, M., ed), pp. 14-44, Academic Titles, Nottingham, UK.
Carter, P. et al., “High LevelEscheria coliExpression and Production of a Bivalent Humanized Antibody Fragment”Bio/Technology(Feb. 1992), vol. 10, pp. 163-167.
Chomecznski et al., “Single Step Method of RNA Isolation by Acid Guanidinium Thiocynate-Phenol—Chloroform Extraction”,Anal. Biochem(1987), vol. 162, pp. 156-159.
Chothia et al. “Canonical Structures for the Hypervariable Regions of Immunoglobulins”,J. Mol. Biol.(1987), vol. 196, pp. 901-917.
Chothia et al., “Structural Repertoire of the Human VH Segments”,J. Mol. Biol.(1992), vol. 227, pp. 799-817.
Foote J. et al., “Antibody Residues Affecting Conformation of the Hypervariable Loops”,J. Mol. Biol.(1992), vol. 224, pp. 487-499.
Hampe et al. “A Novel Monoclonal Antibody Specific for the N-Terminal End of GAD65”,J. Neuroimmunol.(2001), vol. 113, pp. 63-71.
Hansen, J.A. et al., “Monoclonal Antibodies Identifying a Novel T Cell Antigen and la Antigens of Human Lymphocytes”,Immunogenetics(1980), vol. 10, pp. 247-260.
Henikoff S. et al., “Amino Acid Substitution Matrices from Protein Blocks”,Proc. Natl. Acad. Sci. USA(Nov. 1992), vol. 89, pp. 10915-10919.
Jin., L. et al., “High Resolution Functional Analysis of Antibody-Antigen Interactions”,J. Mol. Biol. 1992), vol. 226, pp. 851-865.
Jones, P.T. et al., “Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse”,Nature(1986), vol. 321, pp. 522-525.
Jönsson, U. et al. “Real-time Biospecific Interaction Analysis Using Surface Plasmon Resonance and a Sensor Chip Technology”,BioTechniques(1991), vol. 11, pp. 620-627.
Kabat, et al.,Sequences of Proteins of Immunological Interest,5th ed. 1991, Bethesda: US Dept. of Health and Human Services, PHS, NIH.
Licea, A.F. et al., “Fab Fragments of the Monoclonal Antibody BCF2 are Capable of Neutralizing the Whole Soluble Venom from the ScorpionCentruoides noxius”, Toxicon(1996), vol. 34, No. 8, pp. 843-847.
MacCallum, R.M et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography”,J. Mol. Biol.(1996), vol. 262, pp. 732-745.
Martin, A.C.R. et al., “Structural Families in Loops of Homologous Proteins: Automatic Classification, Modelling and Application to Antibodies,”J. Mol. Biol.(1996), vol. 263, pp. 800-815.
Padlan, E.O et al., “Identification of Specifity-Determining Residues in Antibodies,”FASEB J.(1995), vol. 332, No. 6162, 9, 133-139.
Padlan, E.A., “A Possible Procedure for Reducing the Immunogencity of Antibody Variable Domains while Preserving their Ligand-Binding Properties”Mol. Immunol.(1991), voil. 28, No. 4, pp. 489-498.
Riechmann, et al., “Reshaping Human Antibodies forTherapy”,Nature(1988), vol. 332, pp. 323-327.
Rutgeerts, P. et al., “Efficacy and Safety of Retreatment with Anti-Tumor Necrosis Factor Antibody (Infliximab) to Maintain Remission in Crohn's Disease,”Gastroenterology(1999), vol. 117, pp. 761-769.
Selisko, B., et al., “Antibody BCF2 S Against Scorpion Toxin Cn2 fromCentruoides noxiusHoffman: Primary Structure and Three-Dimensional Model as Free Fv Fragment and Complexed with its Antigen,”Proteins: Structure, Function and Genetics(1999), vol. 37, pp. 130-143.
Tamura, M. et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificty -Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Rentention of SDRs only”,J. Immunol.(2000), vol. 164, pp. 1432-1441.
Tomlinson, I.M. et al., “The Structural Repertoire of the Human Vk Domain”,EMBO J.(1995), vol. 14, No. 18, pp. 4628-4638.
Wu, T.T., et al., “An Analysis if the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complentariity”J. Exp. Med.(1970), vol. 132, pp. 211-250.
Ye, Q, et al., “Gene Synthesis and Expression inE. colifor Pump, a Human Matrix Metalloproteinase”,Biochem, Biophys. Res. Comm.(1992), vol. 186, No. 1, pp. 143-149.
Holmes, M. et al. “Structural effects of framework mutation on a humanized anti-lysozyme antibody”Journal of Immunology(2001) 167(1): 296-301.
Morea, V. et al. “Antibody Modeling: Implication for Engineering and Design”Methods: A Companion to Methods in Enzymology(2000) 20(3):267-279.
Tan, P. et al. “Superhumanized Antibodies: Reduction of Immunogenic Potential by Complementarity-Determining Region Grafting with Human Germline Sequences: Application to an Anti-CD28” Journal of Immunology (2002) 169(2):1119-1125.
Alberts et al.,Molecular Biology of the Cell, 3rdEdition, pp. 1216-1218, 1994.
Carter et al., “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy.”Proc. Natl. Acad. Sci. USA,vol. 89, pp. 4285-4289, May 1992.
Iwahashi et al., “CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity.”Molecular Immunology, vol. 36, pp. 1079-1091, 1999.
Lewin et al.,Genes IV, p. 810, Oxford University Press, 1990.
Mhashilkar et al., “Inhibition of Human Immunodeficiency Virus Type 1 Replication in Vitro in Acutely and Persistently Infected Human CD4+ Mononuclear Cells Expressing Murine and Humanized Anti-Human Immunodeficiency Virus Type 1 Tat Single-Chain Variable Fragment Intrabodies.”Human Gene Therapy, vol. 10, pp. 1453-1467, 1999.
Presta et al., “Humanization of an Antibody Directed Against IgE.”The Journal of Immunology, vol. 151, No. 5, pp. 2623-2632, Sep. 1, 1993.
Riechmann et al., “Single Domain Anti
Arrowsmith Technology Licensing LLC
Blanchard David J.
Townsend and Townsend / and Crew LLP
LandOfFree
Super humanized antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Super humanized antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Super humanized antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4246504